Neurovation Capital

Neurovation Capital is a Boston venture fund that backs early-stage neurotechnology devices and neurology-focused biopharmaceutical platforms, occupying a niche where hardware, software, and biology converge. The Boston base places the fund inside one of the densest medical device and biotech ecosystems in the world, and the dual focus on devices and pharma reflects a practical recognition that meaningful neurological care often requires both. Investments sit within biotech and medical devices, a combination unusual for funds of this scale but appropriate for a category where neurostimulation, brain-computer interfaces, and CNS therapeutics all advance in parallel. Limited public information is available on a named partner roster or detailed portfolio.

The fund participates at Seed and Series A with check sizes of $250k to $1M, positioning Neurovation Capital as an early backer that often co-invests rather than leads larger institutional rounds. Geographic focus is anchored in the United States, with Boston’s clinical and academic networks providing natural deal flow, though neurotechnology’s small global community means the fund considers opportunities wherever credible work is happening. The smaller check profile is consistent with a fund that wants to be early and meaningful rather than a primary lead.

For founders, the relevant question is whether the team is building neurotechnology that requires investor fluency in regulatory pathways, clinical adoption, and the device-software-pharma boundary that defines this category. Neurovation Capital’s value comes from category specialization and Boston-ecosystem proximity rather than capital scale. Teams building generalist medical devices or non-CNS biotech are unlikely fits; teams whose product depends on understanding neurology, neurosurgery, or neurostimulation specifically will benefit from a category-native investor.